logo-loader

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT products post-COVID

Published: 13:09 05 Jun 2020 BST

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building.

In a trading update covering the 12 months to the end of May 2020, the immunodiagnostics specialist noted that its revenue was in line with market expectations.

Oncimmune's strategic pivot aims for robust growth in 2024

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone joins Proactive's Stephen Gunnion with highlights of the company's 2023 performance, which included its strategic decision to focus on its ImmunoINSIGHTS platform. A significant development was the sale of its early lung cancer detection...

1 week, 6 days ago